MONTREAL (AP) — A Quebec City-based research team has received the green light to begin testing a Zika vaccine on humans in collaboration with U.S.-based partners.
The researchers based at Universite Laval are the first in Canada to be authorized by Canada’s federal health agency and the U.S. Food and Drug Administration to conduct clinical tests.
The university is one of three sites that hope to begin testing a vaccine for the mosquito-borne virus in the next few days.
Gary Kobinger, director of Universite Laval’s Infectious Disease Research Centre, said Wednesday the first phase involves administering the vaccine to 40 volunteers spread out over the three sites in Quebec City, Miami and Philadelphia.
The virus has been linked to miscarriages and birth defects in babies born to women who have been infected.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
Filed Under: Drug Discovery
